Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study

被引:35
|
作者
Stefanelli, Paola [1 ]
Bella, Antonino [1 ]
Fedele, Giorgio [1 ]
Pancheri, Serena [2 ]
Leone, Pasqualina [1 ]
Vacca, Paola [1 ]
Neri, Arianna [1 ]
Carannante, Anna [1 ]
Fazio, Cecilia [1 ]
Benedetti, Eleonora [1 ]
Fiore, Stefano [1 ]
Fabiani, Concetta [1 ]
Simmaco, Maurizio [3 ]
Santino, Iolanda [3 ]
Zuccali, Maria Grazia [2 ]
Bizzarri, Giancarlo [2 ]
Magnoni, Rosa [2 ]
Benetollo, Pier Paolo [2 ]
Merler, Stefano [4 ]
Brusaferro, Silvio [5 ]
Rezza, Giovanni [6 ]
Ferro, Antonio [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] APSS Azienda Prov & Serv Sanit, Trento, Italy
[3] St Andrea Univ Hosp, Hosp Direct & Clin Dept, Rome, Italy
[4] Bruno Kessler Fdn, Ctr Informat Technol, Trento, Italy
[5] Ist Super Sanita, Rome, Italy
[6] Minist Hlth, Hlth Prevent Directorate, Rome, Italy
关键词
IgG; Infection fatality rate; Population-based study; SARS-CoV-2; Seroprevalence; SEROPREVALENCE;
D O I
10.1016/j.cmi.2020.11.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy. Methods: All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables. Results: A total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40-49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity. Conclusions: The estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:633.e1 / 633.e7
页数:7
相关论文
共 50 条
  • [21] Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal disease patients with COVID-19
    Wang, Q.
    Wu, Y.
    Wu, L.
    Lu, C.
    Ke, Y.
    Wang, Y.
    Gu, L.
    Shen, Y.
    Tan, W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (05) : 1035 - 1042
  • [22] SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy
    Vinceti, Marco
    Filippini, Tommaso
    Rothman, Kenneth J.
    Di Federico, Silvia
    Orsini, Nicola
    ENVIRONMENTAL RESEARCH, 2021, 197
  • [23] Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
    Krashias, George
    Deeba, Elie
    Constantinou, Astero
    Hadjiagapiou, Maria
    Koptides, Dana
    Richter, Jan
    Tryfonos, Christina
    Bashiardes, Stavros
    Lambrianides, Anastasia
    Loizidou, Maria A.
    Hadjisavvas, Andreas
    Panayiotidis, Mihalis I.
    Christodoulou, Christina
    MICROORGANISMS, 2022, 10 (01)
  • [24] Serosurveillance among COVID-19 Cases in Ahmedabad Using SARS-COV2 IgG Antibodies
    Prakash, Om
    Solanki, Bhavin
    Sheth, Jay
    Maitrak, Daxa
    Kadam, Mina
    Vyas, Sheetal
    Shukla, Aparajita
    Tiwari, Hemant
    INDIAN JOURNAL OF COMMUNITY HEALTH, 2021, 33 (02) : 351 - 356
  • [25] Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
    Pollan, Marina
    Perez-Gomez, Beatriz
    Pastor-Barriuso, Roberto
    Oteo, Jesus
    Hernan, Miguel A.
    Perez-Olmeda, Mayte
    Sanmartin, Jose L.
    Fernandez-Garcia, Aurora
    Cruz, Israel
    Fernandez de Larrea, Nerea
    Molina, Marta
    Rodriguez-Cabrera, Francisco
    Martin, Mariano
    Merino-Amador, Paloma
    Paniagua, Jose Leon
    Munoz-Montalvo, Juan F.
    Blanco, Faustino
    Yotti, Raquel
    LANCET, 2020, 396 (10250): : 535 - 544
  • [26] High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households
    Fritz, Matthieu
    Rosolen, Beatrice
    Krafft, Emilie
    Becquart, Pierre
    Elguero, Eric
    Vratskikh, Oxana
    Denolly, Solene
    Boson, Bertrand
    Vanhomwegen, Jessica
    Gouilh, Meriadeg Ar
    Kodjo, Angeli
    Chirouze, Catherine
    Rosolen, Serge G.
    Legros, Vincent
    Leroy, Eric M.
    ONE HEALTH, 2020, 11
  • [27] National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic
    Palmateer, N. E.
    Dickson, E.
    Furrie, E.
    Godber, I
    Goldberg, D. J.
    Gousias, P.
    Jarvis, L.
    Mathie, L.
    Mavin, S.
    McMenamin, J.
    McNeilly, T. N.
    Murcia, P.
    Murray, J.
    Reid, G.
    Robertson, C.
    Templeton, K.
    von Wissmann, B.
    Wallace, L. A.
    Waugh, C.
    McAuley, A.
    PUBLIC HEALTH, 2021, 198 : 102 - 105
  • [28] Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis
    Indenbaum, Victoria
    Koren, Ravit
    Katz-Likvornik, Shiri
    Yitzchaki, Mayan
    Halpern, Osnat
    Regev-Yochay, Gili
    Cohen, Carmit
    Biber, Asaf
    Feferman, Tali
    Cohen Saban, Noy
    Dhan, Roni
    Levin, Tal
    Gozlan, Yael
    Weil, Merav
    Mor, Orna
    Mandelboim, Michal
    Sofer, Danit
    Mendelson, Ella
    Lustig, Yaniv
    PLOS ONE, 2020, 15 (11):
  • [29] A Population-Based Study of SARS-CoV-2 IgG Antibody Responses to Vaccination in Manitoba
    Martens, Brielle
    Van Caeseele, Paul
    Bullard, Jared
    Loeppky, Carla
    Wei, Yichun
    Reimer, Joss
    Mckinnon, Lyle R.
    Shaw, Souradet Y.
    Kindrachuk, Jason
    Stein, Derek R.
    VACCINES, 2024, 12 (10)
  • [30] Dynamic observation of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID-19 vaccination
    Jiang, Ruiwei
    Dou, Xiaowen
    Li, Min
    Wang, Enyun
    Hu, Jiwen
    Xiong, Dan
    Zhang, Xiuming
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (04)